Ketamine, which has been called “the most important discovery in half a century,” just got a step closer to becoming the first new depression drug in 35 years. Johnson & Johnson, one of the pharmaceutical companies pursuing the drug’s fast-acting antidepressant qualities, presented some promising new research on Saturday that could raise the drug’s profile as a potential treatment for the condition. Read more here.
This article in the Columbian Health Reporter details Todd Walker’s, a middle aged man suffering from major depressive disorder, experience with FDA-approved transcranial magnetic stimulation. Read the article here.